Asian Journal of Pharmaceutical Sciences最新文献

{"title":"Engineered GLUT1-targeted STING polyproagonists: Redox-triggered activation and enhanced endosomal escape for cancer immunotherapy","authors":"Arsalan Raza,&nbsp;Anum Kayani,&nbsp;Guopu Huang,&nbsp;Cheng Li,&nbsp;Qinghao Zhou,&nbsp;Khurshed Bozorov,&nbsp;Yuanyuan Ji,&nbsp;Zhishen Ge","doi":"10.1016/j.ajps.2026.101186","DOIUrl":"10.1016/j.ajps.2026.101186","url":null,"abstract":"<div><div>The stimulator of interferon genes (STING) pathway plays a critical role in bridging innate and adaptive antitumor immunity, representing a promising target in cancer immunotherapy. However, the clinical application of STING agonists is limited by poor pharmacokinetics, low cytosolic delivery efficiency, and immune-related adverse effects. To address these challenges, we developed STING polyproagonist nanoparticles (named GA+S@SR) by self-assembly of an amphiphilic diblock copolymer, P(OEGMA-<em>co</em>-GAMA)-<em>b</em>-PSSRMA, combined with POEGMA-<em>b</em>-P(DEAEMA-<em>co</em>-BMA). The galactose (GA) moieties enable targeted delivery to glucose transporter 1 (GLUT1) on tumor cells, facilitating cellular internalization. The P(DEAEMA-<em>co</em>-BMA) segments promote endosomal escape, followed by the release of the disulfide-linked SR-717 in the cytosol under reducing conditions. This leads to robust activation of the STING pathway, resulting in dendritic cell maturation, enhanced T-cell infiltration, and potent antitumor immunity. Furthermore, when combined with an αPD-L1, this polyproagonist synergistically enhances the efficacy of immune checkpoint blockade, effectively inhibiting primary and distant tumors by counteracting immune evasion. This study highlights the potential of STING polyproagonists in achieving effective cytosolic delivery of STING agonists to boost antitumor immunity and overcome current limitations associated with STING immunotherapy.</div></div>","PeriodicalId":8539,"journal":{"name":"Asian Journal of Pharmaceutical Sciences","volume":"21 4","pages":"Article 101186"},"PeriodicalIF":12.6,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148732685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Janus microneedles enabling orderly vitiligo treatment through spatiotemporal sequential promoting melanogenesis to transfer via PAR2 activation","authors":"Yan Tang,&nbsp;Tiantian Liu,&nbsp;Chuan Wang,&nbsp;Jiajun Xu,&nbsp;Guozhi Zhong,&nbsp;Qian Jing,&nbsp;Jingxin Liu,&nbsp;Fei Gao,&nbsp;Rujing Wang,&nbsp;Mengnan Zhao,&nbsp;Sanjun Shi","doi":"10.1016/j.ajps.2026.101184","DOIUrl":"10.1016/j.ajps.2026.101184","url":null,"abstract":"<div><div>Vitiligo is characterized by a complex pathogenesis involving multiple factors, necessitating therapeutic strategies that simultaneously achieve immune regulation, melanocyte regeneration, and melanosome transfer modulation. Here, we designed a Janus microneedle (Janus MN) based on a core-shell bilayer structure, inspired by the melanin metabolism pathway and the stratified architecture of the skin. The shell of the MN was loaded with a complex of hypericin–assembled nanoparticles (HY-NPs) and astragalus polysaccharides, which preferentially dissolve in the epidermal hair follicle region and basal layer. This intervention ameliorated the microenvironment by scavenging reactive oxygen species and inhibiting CD8⁺ T-cell-mediated immune attacks on melanocytes for repair, while simultaneously activating the MAPK pathway to enhance melanin synthesis in melanocytes for regeneration. The MN core, encapsulated with stabilized trypsin in a hyaluronic acid matrix, targeted the upper epidermal keratinocytes. It activated the PAR2 signaling pathway to enhance melanosome transfer and phagocytosis, thereby promoting visible pigmentation. It integrated dual spatially heterogeneous targets within the epidermis and hair follicles for the first time, achieving multidimensional synergistic intervention through a sequence of “repair, regeneration, and transfer”. Our study provides a novel, spatiotemporally sequential drug delivery strategy for the precise treatment of vitiligo.</div></div>","PeriodicalId":8539,"journal":{"name":"Asian Journal of Pharmaceutical Sciences","volume":"21 4","pages":"Article 101184"},"PeriodicalIF":12.6,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148732202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Injectable dual-affinity self-assembling peptide hydrogels for local controlled delivery of therapeutic antibodies","authors":"Weiping Cui,&nbsp;Limin Zhang,&nbsp;Chang Yang,&nbsp;Bing He,&nbsp;Hua Zhang,&nbsp;Xueqing Wang,&nbsp;Zhiwen Zhang,&nbsp;Qiang Zhang,&nbsp;Wenbing Dai","doi":"10.1016/j.ajps.2026.101189","DOIUrl":"10.1016/j.ajps.2026.101189","url":null,"abstract":"<div><div>Therapeutic monoclonal antibodies have revolutionized the treatment of cancers, infectious diseases and immune disorders; however, their efficacy is compromised by limitations associated with systemic administration, including systemic toxicity, poor patient compliance and inadequate drug concentration at pathological sites. Hydrogels are promising carriers for localized antibody delivery, but conventional formulations fail to simultaneously address the dual challenges of uncontrolled antibody release and insufficient hydrogel retention at the target site. Herein, leveraging a peptide co-assembly strategy, we engineered an injectable dual-affinity self-assembling peptide hydrogel for localized antibody delivery. This hydrogel integrates three components: peptide FEK as the hydrogel matrix, MEP-FEK incorporating 4-mercaptoethylpyridine (MEP) for non-covalent antibody binding, and C₁BP-FEK functionalized with the collagen-binding peptide TKKTLRT for tumor extracellular matrix anchoring. The dual-affinity hydrogel enabled controlled antibody release, exhibiting only 40% cumulative release by Day 90 and an 8.8-fold reduction in initial diffusion rate. In proof-of-concept studies using SKOV3 tumor-bearing mice, the hydrogel carrying trastuzumab as a model therapeutic antibody enhanced local antibody retention, reduced. systemic exposure, exhibited negligible toxicity, and achieved a tumor inhibition rate of 68% This dual-affinity strategy overcomes limitations of conventional affinity-based hydrogels, providing a biocompatible and versatile platform for localized antibody therapy in oncology and other biomedical applications.</div></div>","PeriodicalId":8539,"journal":{"name":"Asian Journal of Pharmaceutical Sciences","volume":"21 4","pages":"Article 101189"},"PeriodicalIF":12.6,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148844490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral probiotic delivery-based therapeutic strategies for inflammatory bowel disease","authors":"Sha Li,&nbsp;Hongdan Deng,&nbsp;Shu Fu,&nbsp;Juan Li,&nbsp;Xinyu Luo,&nbsp;Zhuoping Chen,&nbsp;Pei Wang,&nbsp;Xi Feng,&nbsp;Yi Chen,&nbsp;Chaomei Fu,&nbsp;Zhejie Chen,&nbsp;Shengpeng Wang","doi":"10.1016/j.ajps.2026.101187","DOIUrl":"10.1016/j.ajps.2026.101187","url":null,"abstract":"<div><div>Over the past decade, accumulating evidence supporting the efficacy of probiotics in gut microbiota modulation has spurred interest in their therapeutic potential for inflammatory bowel disease (IBD), a chronic intestinal disorder for which safer and more sustainable alternatives to conventional immunosuppressive and biologic treatments are urgently needed. Probiotics represent a promising therapeutic strategy due to their favorable biosafety profile and compatibility with daily health practices. Mechanistically, probiotics mitigate intestinal inflammation by suppressing pathogenic bacteria, modulating gut immunity and regulating microbial metabolites. However, their application is limited by low viability and poor intestinal colonization following oral administration. To address these challenges, advanced delivery strategies, including physical encapsulation, biohybrid nanocoating and chemical modifications, have been developed to enhance probiotic survival and targeted delivery. Despite these advances, current probiotic delivery systems face limitations, such as the impairment of microbial activity by surface modifications, deficiency in formulating intestinal digestion resistance strategies, lack of strategies for active colonization, and incomplete understanding of therapeutic mechanisms. By addressing these barriers, targeted and sustained research into innovative probiotic delivery systems may yield novel therapeutic approaches for IBD. This review indicates that relying solely on physical encapsulation or simple coating can no longer meet therapeutic demands. Future efforts must shift toward a functional synergy direction, developing multifunctional systems that protect probiotic viability without inhibiting their metabolic and physiological functions while integrating active colonization and targeted release. Furthermore, the review emphasizes the current incompleteness in understanding the therapeutic mechanisms of probiotics and calls for embedding mechanistic studies into the rational design of delivery systems. These insights provide a pathway for the field to move from determining whether live probiotics can be delivered to exploring how to achieve efficient, safe and functionally intact oral probiotic therapy.</div></div>","PeriodicalId":8539,"journal":{"name":"Asian Journal of Pharmaceutical Sciences","volume":"21 4","pages":"Article 101187"},"PeriodicalIF":12.6,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148732205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial intelligence in pharmaceutics: Why prediction without formulation is incomplete","authors":"Alireza Maboudi","doi":"10.1016/j.ajps.2026.101173","DOIUrl":"10.1016/j.ajps.2026.101173","url":null,"abstract":"","PeriodicalId":8539,"journal":{"name":"Asian Journal of Pharmaceutical Sciences","volume":"21 4","pages":"Article 101173"},"PeriodicalIF":12.6,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148732201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Traditional Chinese medicine ingredients integrated microneedles: A promising strategy for transdermal treatment","authors":"Lixia Chen ,&nbsp;Yihua Xu ,&nbsp;Shengfei Yang ,&nbsp;Ninggang Chen ,&nbsp;Jianqing Gao ,&nbsp;Hangjuan Lin","doi":"10.1016/j.ajps.2026.101163","DOIUrl":"10.1016/j.ajps.2026.101163","url":null,"abstract":"<div><div>Traditional Chinese medicine (TCM) has abundant medicinal resources and distinctive pharmacological properties. So, TCM presents considerable promise in clinical treatments. However, challenges such as poor bioavailability hinder broader clinical adoption of TCM. Microneedles (MNs), an innovative and minimally invasive transdermal platform, have emerged to enhance the therapeutic performance of TCM. The integration of MNs with TCM (TCM-MNs) overcomes key limitations of conventional administration routes to reach more targeted and efficient delivery. The structural and compositional diversity of TCM ingredients necessitates diverse TCM-MNs designs, especially “unification of medicines and excipients”. Moreover, TCM-MNs can achieve synergistic benefits when combined with modality-specific interventions, like acupuncture. This review outlines advantages and types of TCM-MNs, according to the special structure and function of TCM components. Current applications of TCM-MNs in different diseases are also discussed. The review offers a promising foundation for the advancement and clinical translation of TCM-MNs in transdermal therapy.</div></div>","PeriodicalId":8539,"journal":{"name":"Asian Journal of Pharmaceutical Sciences","volume":"21 3","pages":"Article 101163"},"PeriodicalIF":11.9,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148245550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nanomaterials: An innovative integrative paradigm for hepatocellular carcinoma adjuvant treatment","authors":"Qingqing Yang ,&nbsp;Wen Zhang ,&nbsp;Keqin Ji ,&nbsp;Zhuo Wang ,&nbsp;Jie Gao ,&nbsp;Jin Ding","doi":"10.1016/j.ajps.2026.101151","DOIUrl":"10.1016/j.ajps.2026.101151","url":null,"abstract":"<div><div>This review systematically examines the application of nanomaterials in adjuvant therapy for hepatocellular carcinoma (HCC) following surgical resection, with the aim of synergistically inhibiting tumor recurrence and driving functional liver regeneration via a 3R paradigm (removing residual tumor cells; remodeling the immune microenvironment; and repairing liver function). This article begins by analyzing the clinical challenges associated with treating HCC on the basis of global epidemiological data and the molecular characteristics of residual micrometastases after surgery. The concept of “precision space-time intervention\" is then introduced, and the design strategies and clinical development of nanomaterials are explored, including targeting, biomimetic, sustained release and degradable designs. Furthermore, this review focuses on the postresection imbalance between tumor recurrence and tissue regeneration in the HCC microenvironment, elucidating the multiscale regulatory mechanisms of liver repair, such as cell differentiation, angiogenesis regulation, maintenance of the cellular redox balance, metabolic reprogramming, and modulation of the inflammatory microenvironment. The temporal dynamics of these mechanisms are emphasized, and the pivotal role of nanomaterials in this context is clarified. The key findings of this review indicate that a multimodal platform with nanomaterials as functional units can integrate diagnosis, hemostasis, antitumor activity and regeneration promotion, thereby overcoming the limitations of monotherapy, which cannot effectively cover the entire process of liver repair. This review breaks through the static intervention model of traditional adjuvant therapy, providing theoretical evidence for the development of multimodal sequential therapeutic nanoplatforms and outlining a clinical translation pathway from the validation of molecular mechanisms to GMP-standard production.</div></div>","PeriodicalId":8539,"journal":{"name":"Asian Journal of Pharmaceutical Sciences","volume":"21 3","pages":"Article 101151"},"PeriodicalIF":11.9,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148153894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Red ginseng-derived nanovesicles to modulate osteoblast and osteoclastogenesis for osteoporosis therapy","authors":"Dong-ha Kim,&nbsp;Se Hwan Mun,&nbsp;Jae-Hee Kwon,&nbsp;Bum-Joon Koo,&nbsp;Hyun-Woo Kim,&nbsp;Sang-Hun Choi,&nbsp;Kwang-Won Seo,&nbsp;Young Yang,&nbsp;Yong Yook Lee,&nbsp;Jin Sun Jung,&nbsp;Do-Kyun Kim,&nbsp;Moon-Chang Baek,&nbsp;Jihoon Kim,&nbsp;Young-Eun Cho","doi":"10.1016/j.ajps.2026.101168","DOIUrl":"10.1016/j.ajps.2026.101168","url":null,"abstract":"<div><div>Osteoporosis is a skeletal disorder characterized by an imbalance between bone formation and resorption, which leads to progressive bone loss and increased fracture risk. While current treatments either inhibit bone resorption or stimulate bone formation, their long-term use is associated with adverse effects, necessitating alternative therapeutic approaches. In this study, we explore the use of red ginseng-derived nanovesicles (RGNVs) as a biocompatible nanotherapeutic strategy for treating osteoporosis. The RGNVs were successfully isolated and characterized, revealing a lipid bilayer structure enriched in bioactive ginsenosides and functional proteins. <em>In vitro</em>, RGNVs enhanced osteoblast proliferation, differentiation, and mineralization while suppressing osteoclast differentiation and bone resorption by modulating the BMP-2/Smad and MAPK signaling pathways. In an ovariectomy-induced osteoporosis mouse model, oral administration of RGNVs significantly restored bone volume and mineral density, and biodistribution studies confirmed their preferential accumulation in the bone tissue. Systemic toxicity evaluation indicated no adverse effects, supporting the safety of RGNVs for therapeutic use. These findings suggest that RGNVs regulate bone remodeling through a dual mechanism, to stimulate bone formation and inhibit bone resorption, thereby offering a promising and well-tolerated approach for osteoporosis management.</div></div>","PeriodicalId":8539,"journal":{"name":"Asian Journal of Pharmaceutical Sciences","volume":"21 3","pages":"Article 101168"},"PeriodicalIF":12.6,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13285656/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148306767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Scavenger receptor–mediated lung-targeted delivery of anti-miR-155 oligoDNA nanomicelles with curcumin for acute lung injury therapy","authors":"Minji Kang,&nbsp;Jihun Oh,&nbsp;Eunjy Kim,&nbsp;Minhyung Lee","doi":"10.1016/j.ajps.2026.101169","DOIUrl":"10.1016/j.ajps.2026.101169","url":null,"abstract":"<div><div>Antisense oligonucleotides offer a powerful strategy for suppressing pro-inflammatory microRNAs, but efficient long-term delivery after systemic administration remains challenging. In this study, we developed a self-assembling oligoDNA-nanomicelle (OD-micelle) platform to simultaneously deliver antisense oligoDNA targeting miR-155 and curcumin, a hydrophobic anti-inflammatory agent, to the lung. The curcumin formulation (OD-micelle/Cur) can be administered intravenously and has a negatively charged surface and average particle size of ∼160 nm, supporting scavenger receptor (SR)-mediated pulmonary delivery. Fluorescence imaging and flow cytometry analyses demonstrated that cellular uptake was comparable to that of OD-micelle/PEI25k, a widely used cationic carrier standard. Hemocompatibility tests demonstrated reduced red blood cell aggregation, compared with PEI25k, indicating improved hemocompatibility without compromising delivery efficiency. Mechanistic studies supported the receptor-dependent transport of the oligoDNA corona. Pre-treatment with excess oligonucleotides reduced the cellular uptake and <em>in vivo</em> lung accumulation of Cy5-labeled OD-micelle/Cur. Furthermore, a RAGE antagonist peptide similarly reduced cellular uptake, suggesting the involvement of RAGE in the SR pathway. In LPS-induced acute lung injury (ALI) mice and LPS-stimulated Raw264.7 cells, the OD-micelle/Cur suppressed the inflammatory response, decreased TNF-α and IL-6 levels, and improved lung histopathology. The antisense oligoDNA corona contributed to the efficacy through miR-155 inhibition, which was confirmed by comparison with scrambled OD-micelle/Cur and increased SOCS1 expression in lung tissue. Furthermore, RAGE pathway inhibition attenuated the inflammatory response, suggesting that RAGE signaling could be an additional therapeutic mechanism. Therefore, OD-micelles are a systemically administrable, lung-targeted oligonucleotide nanoplatform with dual-mechanism anti-inflammatory activity for the treatment of ALI.</div></div>","PeriodicalId":8539,"journal":{"name":"Asian Journal of Pharmaceutical Sciences","volume":"21 3","pages":"Article 101169"},"PeriodicalIF":11.9,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148245913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bispecific antibody vesicles: A multifunctional bioactive drug delivery platform for the treatment of Pseudomonas aeruginosa infection","authors":"Jiaxin Ma ,&nbsp;Zihao Teng ,&nbsp;Xuqi Peng ,&nbsp;Yanyin Wang ,&nbsp;Linyu Ding ,&nbsp;Yijia Xie ,&nbsp;Wenhui Huang ,&nbsp;Qiuyue Long ,&nbsp;Jianzhong Zhang ,&nbsp;Lai Jiang ,&nbsp;Gang Liu","doi":"10.1016/j.ajps.2026.101162","DOIUrl":"10.1016/j.ajps.2026.101162","url":null,"abstract":"<div><div><em>Pseudomonas aeruginosa</em> (<em>P. aeruginosa</em>) is a major pulmonary pathogen that establishes chronic infection through Psl polysaccharide-mediated adhesion and biofilm formation, while accelerating acute disease via toxin injection through the type III secretion system (T3SS) PcrV protein. Conventional small-molecule antibiotics show poor target specificity, limited biofilm penetration and insufficient toxin neutralization, thereby compromising therapeutic efficacy. Here, we developed a bioactive nano delivery system that integrates a bispecific antibody (BsAb) with a nano-antibiotic for <em>P. aeruginosa</em> infection. Specifically, an anti-Psl single-chain variable fragment (scFv) was linked with an anti-PcrV monoclonal antibody (mAb) to generate the BsAb, which was subsequently displayed on cellular outer membranes and harvested as nanoscale membrane vesicles displaying BsAb (BsAb-MVs). Gentamicin (Gen)-loaded poly (lactic-co-glycolic acid) nanoparticles (GNPs) were coated with BsAb-MVs to form BsAb-functionalized GNPs (BsAb-GNPs). By leveraging high-affinity recognition of bacterial surface antigens and enhanced antibiotic penetration, BsAb-GNPs showed robust bactericidal activity by precisely targeting planktonic bacteria and biofilms, imposing effective local drug concentration. Moreover, BsAb-MVs retained antibody-mediated adhesion neutralization and host-cell invasion blockade, thereby mitigating toxin-induced tissue damage. <em>In vitro</em> biofilm assays and a murine pneumonia model confirmed the precise targeting and potent antibacterial efficacy of BsAb-GNPs. Collectively, this antibody-antibiotic system integrated multifunctional antibody-antibiotic therapeutic strategy for biofilm-associated infections and offers immunological advantages, which may provide a scalable and translational strategy against <em>P. aeruginosa</em> biofilm infections.</div></div>","PeriodicalId":8539,"journal":{"name":"Asian Journal of Pharmaceutical Sciences","volume":"21 3","pages":"Article 101162"},"PeriodicalIF":11.9,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148245899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}